Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Revenue (2016 - 2025)

Cardiff Oncology's Revenue history spans 15 years, with the latest figure at $243000.0 for Q4 2025.

  • For Q4 2025, Revenue rose 60.93% year-over-year to $243000.0; the TTM value through Dec 2025 reached $593000.0, down 13.3%, while the annual FY2025 figure was $593000.0, 13.18% down from the prior year.
  • Revenue for Q4 2025 was $243000.0 at Cardiff Oncology, up from $120000.0 in the prior quarter.
  • Across five years, Revenue topped out at $243000.0 in Q4 2025 and bottomed at $68000.0 in Q2 2021.
  • The 5-year median for Revenue is $120500.0 (2025), against an average of $125500.0.
  • The largest annual shift saw Revenue skyrocketed 146.99% in 2024 before it plummeted 46.83% in 2025.
  • A 5-year view of Revenue shows it stood at $133000.0 in 2021, then fell by 3.76% to $128000.0 in 2022, then increased by 21.88% to $156000.0 in 2023, then dropped by 3.21% to $151000.0 in 2024, then soared by 60.93% to $243000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Revenue are $243000.0 (Q4 2025), $120000.0 (Q3 2025), and $121000.0 (Q2 2025).